FIGHTING
Drug Resistant Infections

We are a privately-held clinical-stage biopharmaceutical company developing novel antibacterials targeting drug-resistant pathogens that are deemed a critical priority by the WHO.

Antimicrobial Resistance

A Growing Global Emergency

5–10% of patients

Acquire a healthcare-associated infection in acute care hospitals

1.14M deaths (2021)

Attributable to bacterial AMR

10M deaths / year (2050)

Projected global mortality from antimicrobial resistance

US$412B

Potential annual additional healthcare expenditure globally due to AMR

Who we are

Expert and Complementary Team

Antabio is a clinical stage biopharmaceutical company developing novel antibacterial treatments targeting drug‑resistant infections identified by WHO and CDC as critical priorities, with a particular focus on life-threatening hospital infections.

The company’s lead program, Meropenem-Pilabactam (MEM-PIL, formerly MEM‑ANT3310), is a next‑generation β‑lactam/β‑lactamase inhibitor (BL/BLI) combination designed to treat multi drug-resistant infections in hospital wards and ICUs. Antabio is supported by leading strategic and institutional investors such as the AMR Action Fund, EIC Fund, BNP Paribas Développement, Turenne/Relyens Santé, and IRDI Capital Investment. 

Our mission

Fighting Resistance

Our mission is to develop innovative, highly differentiated antibacterial therapies for patients suffering from severe, hard-to-treat infections caused by multidrug-resistant Gram-negative bacteria.

We focus on delivering effective solutions targeting WHO and CDC priority pathogens, with a particular emphasis on life-threatening hospital-acquired infections. Through scientific excellence, strategic development, and a diversified pipeline, we aim to restore the efficacy of antibiotics and play a leading role in the global fight against antimicrobial resistance. 

Events & Conferences

Where to meet Antabio

AMR Conference on Novel Antimicrobials

23-24 March, 2027
- Basel, Switzerland

The AMR Conference is Europe’s leading business conference dedicated to antimicrobial resistance, bringing together key stakeholders from industry, science, finance, healthcare, and policy to advance AMR innovation.

BIO Partnering at JPM Bio OoO 

11-14 January, 2027
- San Francisco, USA

BIO Partnering™ at JPM Week connects biotech leaders, partners, and investors to foster new business opportunities and collaborations.

Our Pipeline

DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
MEM-PIL
Meropenem-Pilabactam
CRAB, CRE, PA
IV
HAP/VAP
PEi
Pseudomonas Elastase Inhibitors
PA
Inhaled
Chronic respiratory diseases
AGAR-dp 
Antabio-GARDP discovery platform
3 projects, novel MoA
IV / Oral stepdown
HAP/VAP, cUTI
INTABIO-dp 
Antabio internal discovery platform
1 project, novel target
IV / Oral stepdown
HAP/VAP, cUTI